ライフサイエンスコーパス: DR

1 DR is a common complication and a major cause of vision

2 DR progression among those with moderate or worse DR at

3 DR was classified according to Early Treatment Diabetic

4 f youths with T1DM had already received >/=1 DR diagnosis.

5 sts on 373 of these eyes (198 NL, 160 GL, 15 DR).

6 echnique for detecting lipocalin 1 (LCN1), a DR biomarker.

7 ficantly reduced, as were surface HLA-DR and DR-bound KLH-derived peptides.

8 ED1 increased Fos expression in DH, LC, and DR, and DH Fos was decreased by systemic S-propranolol.

9 e collagen-induced arthritis (CIA) model and DR-1 transgenic mice were used to study the importance o

10 er, DH receives strong inputs from LC-NE and DR 5-HT neurons.

11 To assess the relationship between OSA and DR in patients with type 2 diabetes and to assess whethe

12 69 but low levels of human leukocyte antigen DR, CD80, and CD86 at baseline.

13 e-derived chemokine, human leukocyte antigen DR, CD80, and CD86 were increased in abstinent AH patien

14 e-derived chemokine, human leukocyte antigen DR, CD86, and CD80 correlated positively and negatively,

15 /recipient pairs were dog lymphocyte antigen DR-B incompatible (88% of the pairs), and recipient dogs

16 Any DR, vision-threatening DR (VTDR), treatment coverage rat

17 Both, any DR and VTDR showed statistically significant positive as

18 interval [CI]) was 28.2% (25.9-30.6) for any DR, 7.6% (6.5-9.0) for DME, and 7.7% (6.6-9.0) for VTDR.

19 ly associated with higher odds of having any DR (odds ratio, 1.32; 95% CI, 1.06-1.66), mild to modera

20 e sampling weight-adjusted prevalence of any DR and VTDR among non-Indigenous adults with self-report

21 ne also increased the release probability at DR-innervated and STN-innervated synapses, quantified by

22 Automated DR image assessment systems (ARIAS) may provide clinical

23 thm as a novel diagnostic tool for automated DR detection.

24 ased studies with data on photographic-based DR grading, follow-up visits, and well-defined incident

25 5-year progression to VH varied by baseline DR: no DR (1.1%), mild (2.9%), moderate (7.3%), severe N

26 ssion to PDR in 5 years differed by baseline DR: no DR (2.2%), mild (13.0%), moderate (27.2%), severe

27 es MCL homing and invasion and increases CAM-DR through the direct regulation of CXCR4 and FAK expres

28 cell adhesion-mediated drug resistance (CAM-DR) to the same levels as SOX11(-) MCL cells.

29 chrane reviews that addressed AMD, cataract, DR, and glaucoma; were published as of July 20, 2016; an

30 After SS/SS, CD33CD11bHLA-DR MDSCs were dramatically increased out to 28 days (P <

31 s wound complications (NIWCs) after delayed (DR) and secondary reconstruction (SR) compared with imme

32 ber of patients recruited, level of detected DR, change in rates of screening, rate of ophthalmology

33 onically administered loop diuretics develop DR due to compensatory distal tubular sodium reabsorptio

34 pleted the study, and 9 of the 103 developed DR (8.7%).

35 demonstrated that youths with T1DM developed DR faster than youths with T2DM (P < 0.0001).

36 isk alleles have a higher risk of developing DR.

37 ors associated with the hazard of developing DR.

38 ctive man power at a local level to diagnose DR at an early stage.

39 ects in preventing or arresting experimental DR is given.

40 frequency hearing loss (seven with extensive DRs, one with patchy or restricted DRs, and two with no

41 To investigate the role of extrastriatal DRs, we studied their distribution and function in one o

42 In each study eye, DR was classified as mild nonproliferative DR (NPDR; n =

43 of 7655 women) for IR, 5.7% (21 of 369) for DR, and 3.2% (167 of 5150) for SR.

44 ranging from 14 of 19 outcomes (73.7%) (for DR) to 27 of 29 outcomes (93.1%) (for cataract), were al

45 ry 1-point increase in HbA1c, the hazard for DR increased by 20% (HR = 1.20; 95% CI 1.06-1.35) and 30

46 d following a standard national protocol for DR screening and were processed by 3 ARIAS: iGradingM, R

47 T1DM or T2DM exhibit a considerable risk for DR and should undergo regular screenings by eye-care pro

48 prevent avoidable vision loss resulting from DR in Indigenous Australian communities.

49 Awareness of cataract, glaucoma, DR and DED was reported by 31%, 38%, 37% and 52% of the

50 (79.7%) had no DR, 183 patients (11.0%) had DR without a need for an ophthalmology referral, and 155

51 mology referral, and 155 patients (9.3%) had DR with a need for an ophthalmology referral.

52 cific GRS were 2.00-fold more likely to have DR compared with participants in the bottom tertile.

53 erall GRS were 2.56-fold more likely to have DR compared with participants in the lowest tertile.

54 d them as healthy (no retinopathy) or having DR, identifying relevant cases for medical referral.

55 lation-based sample of Latinos with a higher DR prevalence.

56 However, Latinos had a higher DR probability at every year of duration of T2DM (>/= 5

57 64)CuCl2 PET/CT shows a significantly higher DR than (18)F-choline PET/CT.

58 sing T2DM duration is associated with higher DR probability in Latinos than Chinese Americans, even a

59 Both GRSs were associated with higher DR severity levels.

60 d cytokine production was inhibited by a HLA-DR blocking Ab.

61 In this study, we report that activated (HLA-DR(+)) T cells with an effector memory (TEM) profile are

62 ICOS and HLA-DR activation were significantly higher in AA than contr

63 ented by diabetes-susceptible HLA-DQ and HLA-DR molecules, one T cell recognized C-peptide amino acid

64 Six subsets of phagocytic APC (HLA-DR(+)) were consistently observed.

65 vidualized alloimmune risk determined by HLA-DR/DQ epitope mismatch.

66 terestingly, these CD45(+)CD33(+)CD11b(+)HLA-DR(-) MDSCs exhibited increased CXCR2 expression compare

67 mune activation (percentages of CD4+CD38+HLA-DR+ and CD8+CD38+HLA-DR+ T cells).

68 ; 95% CI = 1.01-2.05; P = .045) and CD38+HLA-DR+ CD8+ T cells (1.40 fold-change in integrated HIV DNA

69 ated HIV DNA per 1-unit increase in CD38+HLA-DR+ CD8+ T cells; 95% CI = 1.05-1.86; P = .02).

70 entages of CD4+CD38+HLA-DR+ and CD8+CD38+HLA-DR+ T cells).

71 D8+CD28-, CD4+CD38+HLA-DR+, and CD8+CD38+HLA-DR+ T cells, dehydroepiandrosterone sulfate, free testos

72 ntages of CD4+CD28-, CD8+CD28-, CD4+CD38+HLA-DR+, and CD8+CD38+HLA-DR+ T cells, dehydroepiandrosteron

73 We determined CD38+HLA-DR+CD8+ (activated) T-cell frequency, and plasma levels

74 Using flow cytometry expression of CD38, HLA-DR and PD-1 were measured in blood (n = 48), lymph node

75 ive [CD3, CD14, CD16, CD19, CD20, CD56], HLA-DR+, CD304, CD11c, ILT3 and CD86).

76 ts treated with tacrolimus who developed HLA-DR/DQ dnDSA had a higher proportion of tacrolimus trough

77 genes, including mutations of different HLA-DR family members affecting OX40 signaling pathway, whic

78 ation of CD11b+ myeloid cells expressing HLA-DR, CD11c, and CX3CR1.

79 Adjusting for HLA-DR-DQ and ancestry, higher childhood 25(OH)D was associa

80 d to be significant after adjustment for HLA-DR/DQ eplet mismatch.

81 Furthermore, HLA-DR molecules encoded by shared-epitope (SE) alleles were

82 ,011 serial tacrolimus trough levels had HLA-DR/DQ eplet mismatch determined using HLAMatchmaker soft

83 ocompatibility complex class II (MHC-II; HLA-DR)-dependent manner.

84 on of IPF PBMC cultures also resulted in HLA-DR-dependent production of IgG with anti-vimentin specif

85 ace expression of APC-associated markers HLA-DR and CD86.

86 We identified cDC2 as the major mature (HLA-DR(hi)) subset in LNs with the highest frequency in lung

87 l CD4(+) T cell Ag-presentation molecule HLA-DR within the human lung, and that this expression can b

88 pulsed MoDC contained significantly more HLA-DR and KLH than those purified from control MoDC, and KL

89 Upregulation of HLA-DR on neutrophils required the presence of the antigen-s

90 fore dnDSA development in the context of HLA-DR/DQ eplet mismatch.

91 We collected data on HLA-DR, DQ genotypes of 31,766 infants, born from 1993 throu

92 egulate M1 polarization markers (CD80 or HLA-DR) on either tissue type.

93 ut a family history of T1D (P = 0.39) or HLA-DR-DQ genotypes (P = 0.74).

94 we found that the stimulation of OX40L, HLA-DR, and CD83 expressions in DC induced by the Th2-promot

95 CD14(pos)HLA-DR(low/neg) monocytic (M)-MDSCs were expanded in intensi

96 body positivity, sex, selected high-risk HLA-DR-DQ genotypes, relationship to a family member with T1

97 age of the population and the high-risk HLA-DR-DQ subtypes studied.

98 s significantly reduced, as were surface HLA-DR and DR-bound KLH-derived peptides.

99 We conclude that HLA-DR/DQ eplet mismatch and tacrolimus trough levels are in

100 sp. and Parabacteroides sp., whereas the HLA-DR-presented FLNA peptide has homology with epitopes fro

101 The HLA-DR-presented GNS peptide has marked sequence homology wi

102 rption, but whether this translates to human DR is unknown.

103 Americans and Latinos had a nearly identical DR probability based on HbA1c and SBP.

104 ase 3 trial done in Lisungi health centre in DR Congo, and Kazo health centre in Uganda in 2012-14.

105 atment for DME may experience improvement in DR severity.

106 Patients with better basic knowledge in DR and memorizing their HbA1c level showed a higher prop

107 ion, and no consistent evidence of increased DR progression in patients ever treated with TZDs vs tho

108 e ubiquitously expressed Dyn2, TRAIL-induced DR endocytosis is selectively regulated by activation of

109 Baseline severities and features of initial DR are prognostic for PDR development.

110 Two weeks after injury, injured DRs of induced animals contained far more SCs and SC pro

111 whether ARIAS can be safely introduced into DR screening pathways to replace human graders.

112 I and NIWCs after implant and autologous IR, DR, and SR breast procedures after mastectomy.

113 levance of the inverted repeat structure (IR/DR) in a subgroup of the Tc1/mariner superfamily of tran

114 er suppresses single-ended reactions, the IR/DR orchestrates a regulatory mechanism to enforce synaps

115 ation of internally deleted copies in the IR/DR subgroup, including Sleeping Beauty (SB).

116 Translating IR/DR regulation to in vitro evolution yielded an SB transp

117 of the differentiation machinery because its DR makes cells more prone to adipogenic differentiation

118 While we observed an overall lower DR prevalence in Chinese Americans than in Latinos (35.8

119 atistically significant improvements in mean DR severity compared with sham treatment at months 6, 12

120 udy levels 10-15; n = 154), mild to moderate DR (levels 20-43; n = 112), and severe DR (levels >/=53

121 , 1.32; 95% CI, 1.06-1.66), mild to moderate DR (odds ratio, 1.30; 95% CI, 1.01-1.68), and severe DR

122 R severity by ETDRS photos was 24 (19.0%) no DR, 48 (38.1%) mild NPDR, and 54 (42.9%) moderate NPDR.

123 progression to VH varied by baseline DR: no DR (1.1%), mild (2.9%), moderate (7.3%), severe NPDR (9.

124 o PDR in 5 years differed by baseline DR: no DR (2.2%), mild (13.0%), moderate (27.2%), severe nonpro

125 [12.7] years), 1323 patients (79.7%) had no DR, 183 patients (11.0%) had DR without a need for an op

126 2-field retinal images into categories of no DR (Early Treatment Diabetic Retinopathy Study levels 10

127 In comparison to no DR, the eyes with mild, moderate, and severe NPDR were 2

128 and at the DVP decreased in patients with no DR from 0.361 (0.019) to 0.345 (0.020) in patients with

129 eased from 0.358 (0.017) in patients with no DR to 0.338 (0.012) in patients with proliferative DR (P

130 creased from 1.53 (0.05) in patients with no DR to 1.60 (0.05) in patients with proliferative DR (P <

131 creased from 1.55 (0.06) in patients with no DR to 1.61 (0.05) in patients with proliferative DR (P =

132 th patchy or restricted DRs, and two with no DR) were tested.

133 Compared with no DR, the patient eyes that presented with mild, moderate,

134 95% CI, 1.16-3.07; P = .01) nonproliferative DR were more likely to have fallen.

135 0 participants (495 [76.2%] nonproliferative DR [NPDR], 155 proliferative DR [PDR]) were analyzed; 30

136 , DR was classified as mild nonproliferative DR (NPDR; n = 32 [38%]), moderate-to-severe NPDR (n = 31

137 hy (DR) or mild or moderate nonproliferative DR (NPDR).

138 on between mild to moderate nonproliferative DR and falling will be required to confirm these finding

139 The eyes with moderate nonproliferative DR but without DME exhibited a wide range of TRBF from 3

140 resence of mild to moderate nonproliferative DR was independently associated with an increased likeli

141 c retinopathy (DR), 47 with nonproliferative DR (NPDR), 51 with NPDR and diabetic macular edema (DME)

142 e glutamate afferents: dorsal raphe nucleus (DR), pedunculopontine nucleus (PPN), and subthalamic nuc

143 are many undiagnosed and untreated cases of DR.

144 health care economies and to aid delivery of DR screening in developing or remote health care setting

145 Distribution of DR severity by ETDRS photos was 24 (19.0%) no DR, 48 (38

146 n C. elegans, we investigated the effects of DR as well as manipulations of insulin, mechanistic targ

147 As such, the beneficial effects of DR on learning can be attributed to changes in a nutriti

148 the importance of preventing severe forms of DR to mitigate the vision-related functional burden amon

149 these risk factors may reduce the impact of DR in Asia, regardless of ethnicity.

150 (37.7%) with ranibizumab had improvement of DR severity (adjusted difference: 11.7%; 95% CI, 2.9% to

151 t the SVP and DVP for each severity level of DR and the association of systemic risk factors vs the C

152 cteristics associated with varying levels of DR.

153 The lipid profile of the livers of DR mice is correspondingly shifted towards lowered trigl

154 tions as high priority for the management of DR, including DME, but few were associated with Cochrane

155 sion analyses based on a conceptual model of DR risk identified factors associated with prevalent DR.

156 R analogs reported in experimental models of DR.

157 I, 1.53-2.02 per decade) had greater odds of DR requiring an ophthalmology referral.

158 ation may play a role in the pathogenesis of DR in many but not in all patients with type 2 diabetes.

159 feedback that resembles the pathogenesis of DR.

160 pressing SCs, enabling robust penetration of DR axons into the spinal cord.

161 pond to the early neurodegenerative phase of DR.

162 The presence of DR decreased the overall RT by 13.04-16.63 mum.

163 ian Singaporeans have a higher prevalence of DR and DME compared with Chinese and Malays.

164 egative results regarding the progression of DR in the SUSTAIN-6 study, as well as the gaps that stil

165 s against the development and progression of DR lesions are reviewed.

166 will prevent or slow down the progression of DR.

167 treatments were associated with low rates of DR worsening.

168 ently low in the eyes with DME regardless of DR severity.

169 to diabetes care may help reduce the risk of DR.

170 ignificantly associated with higher risks of DR, independent of traditional risk factors.

171 ystem to assess the presence and severity of DR following a standardized protocol.

172 n between perceived barriers and severity of DR in the worse-affected eye.

173 Severity of DR was graded as none, minimal, mild, moderate, and visi

174 ng system to assess presence and severity of DR.

175 re independently associated with severity of DR.

176 ng to determine the presence and severity of DR.

177 examine the association of severe stages of DR (DME and PDR) with incident CVD in patients with type

178 WSR and WSS were lower in all stages of DR (P </= 0.05), suggestive of the potential of WSS as a

179 disease (CVD) focused on the early stages of DR.

180 dified Airlie House classification system of DR.

181 e, we identified the incidence and timing of DR onset.

182 general patient wishes for the treatment of DR confirmed the concept of SDM, which was favored by th

183 hows an urgency to gather a national data on DR, raise awareness among diabetics and train effective

184 at the impact of increasing HbA1c and SBP on DR probability is incrementally the same in both populat

185 do not respond to either EGFR antagonist or DR agonist monotherapies.

186 ures were incidence or progression of DME or DR and change in visual acuity.

187 50.4 [8.5] years); 61.4% of women had IR or DR.

188 Prep1 DR expands the DNA binding landscape of C/EBPbeta (CCAAT

189 identified factors associated with prevalent DR.

190 Preventing DR TB-related catastrophic costs will require considerab

191 onproliferative DR [NPDR], 155 proliferative DR [PDR]) were analyzed; 302 (46.5%) were women and mean

192 severe NPDR (n = 31 [37%]), or proliferative DR (n = 21 [25%]).

193 of severe nonproliferative or proliferative DR, or clinically significant macular edema (CSME).

194 SA to develop preproliferative/proliferative DR (18.4% vs. 6.1%; P = 0.02).

195 rogression to preproliferative/proliferative DR (odds ratio, 5.2; 95% CI confidence interval, 1.2-23.

196 reduction in preproliferative/proliferative DR.

197 ly to develop preproliferative/proliferative DR.

198 rogression to preproliferative/proliferative DR.

199 0.338 (0.012) in patients with proliferative DR (P < .001) and at the DVP decreased in patients with

200 o 1.60 (0.05) in patients with proliferative DR (P < .01) and at the DVP increased from 1.55 (0.06) i

201 o 1.61 (0.05) in patients with proliferative DR (P = .02).

202 0.345 (0.020) in patients with proliferative DR (P = .04).

203 cular edema (DME), and 18 with proliferative DR (PDR)-and 64 age-matched nondiabetic control eyes.

204 roportion of participants with proliferative DR [PDR], clinically significant macular edema [CSME], o

205 ad no benefit on the primary outcome (HVLT-R-DR; difference in means -0.43 [95% CI -1.73 to 0.87]).

206 Dorsal raphe (DR) harbors cell bodies of serotonin-producing neurons t

207 and by the appearance of ductular reaction (DR) as the results of hepatic progenitor cell activation

208 that a bile acid-induced ductular reaction (DR) drives fibrogenesis.

209 ells expressing its cognate death receptors (DRs).

210 In Nepal, there are less studies regarding DR and they too are limited around Kathmandu valley.

211 c differentiation since its down-regulation (DR) in both ex vivo bone marrow-derived mesenchymal stro

212 ntries, and additionally for drug-resistant (DR) TB-related costs in 1 of the 7 countries with availa

213 extensive DRs, one with patchy or restricted DRs, and two with no DR) were tested.

214 Caenorhabditis elegans, dietary restriction (DR) grants numerous benefits, including enhanced learnin

215 Dietary restriction (DR), a reduction in food intake without malnutrition, in

216 betic patients without diabetic retinopathy (DR) after 1 year of follow-up.

217 ociated with prevalent diabetic retinopathy (DR) among Chinese American adults with type 2 diabetes m

218 of microRNAs (miRs) in diabetic retinopathy (DR) and age-related macular degeneration (AMD) remains u

219 e relationship between diabetic retinopathy (DR) and cardiovascular disease (CVD) focused on the earl

220 s; cataract, glaucoma, diabetic retinopathy (DR) and dry eye disease (DED) was assessed.

221 ding to vision loss in diabetic retinopathy (DR) are highlighted.

222 glaucoma (GL), and 18 diabetic retinopathy (DR) at Tilganga Institute of Ophthalmology, Kathmandu, N

223 A diabetic retinopathy (DR) biomarker, tumor necrosis factor-alpha was selected

224 , annual screening for diabetic retinopathy (DR) by expert human grading of retinal images is challen

225 vascular hallmarks of diabetic retinopathy (DR) due to BRB disruption.

226 DME) favorably affects diabetic retinopathy (DR) improvement and worsening.

227 e and risk factors for diabetic retinopathy (DR) in the Singapore Epidemiology of Eye Diseases (SEED)

228 screening to check for diabetic retinopathy (DR) is important to prevent vision loss in persons with

229 Diabetic retinopathy (DR) is one of the leading causes of preventable blindnes

230 Early diagnosis of diabetic retinopathy (DR) is vital but challenging.

231 esence and severity of diabetic retinopathy (DR) may contribute to the risk of falling in persons wit

232 of 69 patients with no diabetic retinopathy (DR) or mild or moderate nonproliferative DR (NPDR).

233 tratifying by baseline diabetic retinopathy (DR) severity and adjusting for age, sex, race, and start

234 inopathy Study (ETDRS) diabetic retinopathy (DR) severity scale (DRSS) grade during the Fluocinolone

235 ing the progression of diabetic retinopathy (DR) were neutral with liraglutide (LEADER) or worse when

236 the classical sign of diabetic retinopathy (DR) which is one of the leading causes of blindness, esp

237 abetic eyes-27 with no diabetic retinopathy (DR), 47 with nonproliferative DR (NPDR), 51 with NPDR an

238 Diabetic retinopathy (DR), a major microvascular complication of diabetes, lea

239 have value in managing diabetic retinopathy (DR), but there is limited information on the ability of

240 nic diseases including diabetic retinopathy (DR), mitophagy dysregulation and NLRP3 inflammasome acti

241 maculopathy including diabetic retinopathy (DR), retinal vein occlusion (RVO), and neovascular-age r

242 ovasculopathy based on diabetic retinopathy (DR).

243 cesses before treating diabetic retinopathy (DR).

244 eir risk of developing diabetic retinopathy (DR).

245 n were investigated in diabetic retinopathy (DR).

246 y robust risk loci for diabetic retinopathy (DR).

247 ect his or her risk of diabetic retinopathy (DR); however, few studies have examined this association

248 ation [AMD], cataract, diabetic retinopathy [DR], and glaucoma) and the overlap between outcomes in t

249 nephrine (LC-NE) and dorsal raphe serotonin (DR 5-HT) systems.

250 erate DR (levels 20-43; n = 112), and severe DR (levels >/=53 and/or presence of clinically significa

251 ratio, 1.30; 95% CI, 1.01-1.68), and severe DR (odds ratio, 1.36; 95% CI, 1.03-1.79).

252 was confirmed in subgroups with more severe DR and chronic DME at baseline.

253 Our results indicate that DR remodels genome-wide patterns of DNA methylation so t

254 Our results indicated that DR was more extended, appeared earlier, and had a higher

255 We propose that DR serotonergic neurons preempt reward delays at the dec

256 The DR was evaluated by cytokeratin-7 immunohistochemistry i

257 nd resection, and decreased HR repair in the DR-GFP DSB repair model.

258 y differentiation and the development of the DR, with subsequent induction of chemokines that drive H

259 dren with CFLD, and it demonstrated that the DR was significantly correlated with hepatic fibrosis st

260 The DRs of (18)F-choline PET/CT and multiparametric MRI were

261 The difference between the DRs of (64)CuCl2 PET/CT and (18)F-choline PET/CT was sta

262 ole in the pathogenesis of sight-threatening DR (STDR).

263 Any DR, vision-threatening DR (VTDR), treatment coverage rates (proportion of parti

264 rs associated with DR and vision-threatening DR (VTDR).

265 tients with DME, PDR, and vision-threatening DR, compared with persons without these conditions, by u

266 s by eye-care professionals to ensure timely DR diagnosis and limit progression to vision-threatening

267 ically the rate of vision loss attributed to DR.

268 also extracted outcome measures relevant to DR and asked respondents to identify those that must be

269 ene expression and lipidomics in response to DR and aging in female mouse liver.

270 TRAIL-DR-mediated ryanodine receptor activation and endocytosi

271 hosphorylation and activation of Dyn1, TRAIL-DR endocytosis, and increased resistance to TRAIL-induce

272 ptosis-inducing ligand-death receptor (TRAIL-DR) complexes in several cancer cells.

273 f drug-resistant Mycobacterium tuberculosis (DR-TB) are critical global health issues.

274 , we successfully used REP to detect the two DR biomarkers on the same platform.

275 The precise mechanisms by which DR engenders benefits on processes related to learning r

276 However, the mechanisms by which DR interacts with the aging process to improve health in

277 intervals (CIs) for factors associated with DR and vision-threatening DR (VTDR).

278 ssess if risk of falling was associated with DR severity.

279 y prevent the loss of vision associated with DR.

280 DME, 48.8 (13.4) microL/min in the eyes with DR but without DME, 40.1 (7.7) microL/min in the diabeti

281 This study included 41 eyes with DR from 31 diabetic patients (mean [SD] age, 62.8 [13.4]

282 anuary 11, 2016, which analyzed 41 eyes with DR from 31 diabetic patients, 20 eyes without DR from 11

283 ent of retinal vascular changes in eyes with DR that are correlated to visual acuity.

284 Referral of eyes with DR to an ophthalmologist for further evaluation and trea

285 er longitudinal studies of TRBF in eyes with DR would be helpful to determine whether reduced TRBF is

286 ive maculopathy were evaluated; 60 eyes with DR, 9 eyes with RVO, and 5 eyes nvAMD, 1 eye with macroa

287 the ability of OCTA to distinguish eyes with DR.

288 Associations between the GRSs with DR were determined using logistic regression analyses.

289 to assess visual morbidity in patients with DR at a peripheral tertiary eye care center of Nepal.

290 ess to care for minorities and patients with DR requiring treatment.

291 In multivariable models, those with DR were more likely to have fallen (odds ratio [OR], 1.3

292 tients with type 2 diabetes with and without DR (n = 100 eyes).

293 with participants with diabetes but without DR, those with mild (OR, 1.81; 95% CI, 1.23-2.67; P = .0

294 pared with persons with diabetes but without DR.

295 s; 12 were female patients), 20 eyes without DR from 11 diabetic patients (mean [SD] age, 58.8 [10.1]

296 R from 31 diabetic patients, 20 eyes without DR from 11 diabetic patients, and 16 eyes from 12 health

297 cipants with type 2 diabetes with or without DR and the eyes of participants without diabetes from Se

298 ciations were found for participants without DR compared with those with no diabetes.

299 Diabetic patients without DR showed a thicker choroid and a thinner retina, partic

300 ogression among those with moderate or worse DR at baseline was no different between TZD users and no